CDH2 and prostate carcinoma: Numerous studies have shown that ADT can result in an increase in expression of mesenchymal markers such as vimentin, N-cadherin and TWIST1, and a decrease in epithelial markers, especially E-cadherin, in prostate cancer PDX model and patient tumours (Nouri et al., 2014).